Welcome to Medications.com

ROUNDUP AstraZeneca's strengthened pipeline fails to impress as ... - Forbes

... chief financial officer Simon Lowth predicted that revenues from MedImmune would cancel out losses incurred from generic competition to Toprol-XL in 2008.

http://www.forbes.com/markets/fee... | Posted: Thu Jan 31 11:14:04 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea